Palatin Technologies, Inc. (OTCMKTS:PTNT – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $17.78 and traded as high as $24.94. Palatin Technologies shares last traded at $24.88, with a volume of 629 shares changing hands.
Palatin Technologies Stock Performance
The stock’s 50-day moving average is $25.13 and its two-hundred day moving average is $17.91. The company has a market capitalization of $996,400.00, a PE ratio of -16.07 and a beta of -1.47.
About Palatin Technologies
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy.
Further Reading
- Five stocks we like better than Palatin Technologies
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
